“3D視覺第一股”奧比中光(688322.SH)首日上市一度漲57% 市值逼近200億
格隆匯7月7日丨3D視覺感知龍頭奧比中光(688322.SH)今日正式在科創板掛牌上市,盤初最高漲超57%報48.9元,市值逼近200億元。公開資料顯示,奧比中光的主營業務是3D視覺感知產品的設計、研發、生產和銷售,公司主要產品包括3D視覺傳感器、消費級應用設備和工業級應用設備。招股書顯示,2019-2021年,奧比中光的營收分別為5.97億元、2.59億元及4.74億元。2020年營收下滑主因新冠疫情影響帶來收入短暫下降,但2021年營收強勢反彈,同比增83.11%。更值得注意的是,奧比中光預計未來3年左右年度營收有望達到14.9億元,同時有望實現盈虧平衡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.